Blood and Urine DNA Tests to Track Upper Urinary Tract Cancer Recurrence
Studies tumor DNA in blood and urine to check for cancer after surgery in adults.
Plain-language title generated from the registry record
Registry title: Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- RenJi HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT05595408
- Record updated
- 9 December 2025
- Original description
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.Read full original descriptionShow less
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma(CURATE-UTUC): A Multicenter Prospective Longitudinal Cohort Study
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.
Inclusion: pathological comfirmed T2-4 or N+ and M0 upper tract urothelial carcinoma; Male or female aged ≥18 years old who are willing to sign the informed consent form; have no distant metastasis; have an ECOG 0 to 2; upper tract urothelial carcinoma patients received radical nephroureterectomy; have no multiple primary carcinoma; received adjuvant chemotherapy or immunotherapy after surgery within 12 weeks; ≥2 postoperative liquid biopsy assessments (T1 and T2).
Exclusion: a prior history of bladder or synchronous bladder cancer; Neoadjuvant therapy exposure; Severe infection; Severe heart disease; Uncontrollable neurological or mental disorders; Severe diabetes mellitus; Patients with severe autoimmune diseases; Pregnant or lactating women, or patients who are fertile but do not take contraceptive measures; No bilateral UTUC; Surveillance time < month; <2 postoperative MRD surveillance assessments.